Every engagement is scoped and priced independently. No partnership commitment, no minimum volume, no exclusivity. Choose the depth that fits your program today — expand only when a specific opportunity warrants it.
Level 01 and 02 are the natural entry points. Level 03 and 04 exist for programs that want to go deeper — separate conversations when a specific program warrants it.
Analyze your data, deliver full cell profiles, and produce targeted recommendations to improve your system.
You oversee and execute any implementation.
The right entry point when you have strong internal capability and want fast, mechanism-backed intelligence to inform your team's decisions.
Level 01, plus specific R&D, chemistry, and process recommendations linked directly to functional improvements or technical milestones — for example, target improvements in titer, novel biomarkers, or CQA stability.
Recommendations become specifications — with support through scaling and toward commercial deployment.
Level 02, plus we handle testing and validation of full formulations using high-throughput approaches and scaled bioreactor runs where appropriate.
Media, feed, reagent, and ancillary materials formulation, testing, and scale-up — under one engagement.
Level 03, plus scaled production coordination to commercial endpoints for your program. cGMP, clinic-ready, and scaled results.
We handle the entire value chain — from cellular intelligence through to commercial-ready program.
Commercial structures are flexible. Every engagement is scoped to your program, priorities, and economics — usually comprising one or :.
Fixed pricing based on engagement phases and defined KPIs. Predictable cost and timeline — the most common structure for scoped pilots and Level 01–02 engagements.
Payments tied to phase completion and technical milestone achievement. Balances predictable structure with shared alignment on outcomes — common in Level 03 co-development engagements.
Structures based on KPIs and commercial endpoints — allowing more of the value to be captured at outcome rather than upfront. A good fit for teams with smaller near-term budgets and clear commercial goals.
Instead of layered service tiers and enterprise vendor pricing, you get more comprehensive and higher-quality deliverables. Complete R&D, process, and product development under one engagement — at total commercial obligations meaningfully below comparable partnerships.
Cellular intelligence at commercial scale isn't a solo effort. VHL's platform is delivered in partnership with a curated network — from sequencing to formulation to manufacturing — chosen because they're the best at what they do.
Coordinated multi-omic sequencing for every engagement where VHL runs analytics from samples. Rapid turnaround, cost-effective per-sample economics, quality data ready for the platform pipeline.
High throughput bioreactor infrastructure for testing recommended process conditions for new feed strategies, and media formulations. Rapid turn-around between platform recommendation and bioreactor validation.
High-throughput ingredient screening and performance validation. Prototype batch production for formulation candidates.
Contract media manufacturing from pilot through commercial scales for novel formulations designed by the VHL platform. GMP-capable, ingredient-transparent, fully scalable, ready for programs headed to clinic or commercial.
Custom media manufacturing with cost-optimized economics. When programs need custom formulations at scale without enterprise vendor pricing.
Chemically-defined media CMO specifically engineered for microbial systems. Purpose-built for the entire range of eukaryotic and prokaryotic microbial programs for solid and liquid media.
Strategic partnerships with cGMP-capable CDMOs across mammalian bioprocessing and cell therapy — spanning Europe, APAC, and the US. For engagements looking to hand off production.
Every engagement is scoped to leverage the right partners for your specific program, needs, and budget.
We're one of the few companies that provides ingredient transparency and flexible IP structures for novel formulations we produce. Process, product, media, and manufacturing improvements we deliver become new IP assets for your company.
You see the formulation. Every component, every source, every rationale — documented and delivered. No black box between you and your process.
Make new IP your new commercial asset. Novel formulations we produce for you come with many options — structured per engagement.
Your process is just as important as your product. Process, product, media, and manufacturing improvements we deliver become new IP estate for your company which can increase your enterprise value
Actual terms are mapped per engagement based on your specific commercial structure. This page describes our general approach.
The workflow is the same whether you're running a scoped pilot or a multi-phase partnership — structured, fast, and designed to deliver value from the first data handoff.
A 30-minute call to understand your program, your cells, and your goals. Scoped within a few business days.
Send existing RNA-seq / multi-omic data, or ship samples out for VHL-coordinated extraction and sequencing via our preferred vendor.
Full multi-omic characterization, digital twin, and prioritized recommendations. Days, not months.
Optimize, develop, and scale.
Engagement level, scope, structure, and pricing are scoped independently per engagement — meeting your program where it is today.
Tell us about your program.
Start a conversation →